Skip to Main Content

Author Details

Deanna L Kroetz
University of California San Francisco
1993
131
45
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36695358Host variation in type I interferon signaling genes (MX1), C-C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers predict viral reservoir size.AIDS2023
34481421Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies.Basic Clin Pharmacol Toxicol2022
35488474New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium.Clin Pharmacol Ther2022
34853435Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.Br J Cancer2022
34616010Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.Br J Cancer2022
33326171GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.Clin Transl Sci2021
34528148Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein.AAPS J2021
34625255In-depth triacylglycerol profiling using MS<sup>3</sup> Q-Trap mass spectrometry.Anal Chim Acta2021
33142018Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy.Clin Transl Sci2021
33340242Human Induced Pluripotent Stem Cell Derived Sensory Neurons are Sensitive to the Neurotoxic Effects of Paclitaxel.Clin Transl Sci2021
32562552Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.Clin Pharmacol Ther2020
32275773P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer.Clin Pharmacol Ther2020
31138120Efficient estimation of grouped survival models.BMC Bioinformatics2019
31639417Reversible inhibition of efflux transporters by hydrogel microdevices.Eur J Pharm Biopharm2019
32391517A Practical First Step Using Needs Assessment and a Survey Approach to Implementing a Clinical Pharmacogenomics Consult Service.J Am Coll Clin Pharm2019
30107040Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.Clin Pharmacol Ther2019
30260474A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).Clin Pharmacol Ther2019
30982223Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.Clin Transl Sci2019
30910922Apical Shear Stress Enhanced Organic Cation Transport in Human OCT2/MATE1-Transfected Madin-Darby Canine Kidney Cells Involves Ciliary Sensing.J Pharmacol Exp Ther2019
27845419ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.Pharmacogenomics J2018
29973058CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.AIDS Res Hum Retroviruses2018
29871907Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).Clin Cancer Res2018
29467213Rare Variants in the <i>ABCG2</i> Promoter Modulate In Vivo Activity.Drug Metab Dispos2018
29105855Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.Br J Clin Pharmacol2018
29278617Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.Pharmacogenet Genomics2018
28882537Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.Pharmacol Ther2018
28612269Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.Clin Pharmacokinet2018
26856248Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines.Pharmacogenomics J2017
28930109ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression.Pharmacogenet Genomics2017
27981569Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy.Clin Pharmacol Ther2017
27856528In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus.Drug Metab Dispos2017
27088321Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans.AIDS2016
26678255Transforming Translation: Impact of Clinical and Translational Science.Clin Transl Sci2016
26497925Multidrug resistance-associated protein 4 is a determinant of arsenite resistance.Oncol Rep2016
27447836Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1.Clin Pharmacol Ther2016
27143689Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.Clin Cancer Res2016
27546282Best Practices for Clinical and Translational Research and Implementation.Clin Transl Sci2016
25766675SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients.Neurobiol Dis2015
26015512Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy.Clin Cancer Res2015
25647431PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.Pharmacogenet Genomics2015
24184504ABCC4 is regulated by microRNA-124a and microRNA-506.Biochem Pharmacol2014
25521360Genomic architecture of pharmacological efficacy and adverse events.Pharmacogenomics2014
24513692Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).Pharmacogenomics J2014
24561393Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.Clin Pharmacol Ther2014
24625462PharmGKB summary: abacavir pathway.Pharmacogenet Genomics2014
24346422Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".Clin Pharmacol Ther2014
24343710Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention.J Clin Pharmacol2014
20639796Genome-wide association studies in pharmacogenomics: successes and lessons.Pharmacogenet Genomics2013
24092818Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway.Mol Pharmacol2013
23863877Association of CYP2C9*2 with bosentan-induced liver injury.Clin Pharmacol Ther2013
  • 1 - 50 of 131

Recommended Authors

University of California San Francisco
Career Start Year 2009
Number of shared co-authors 10
Federal Institute for Drugs and Medical Devices (BfArM)
Career Start Year 2008
Number of shared co-authors 0
Vanderbilt University Medical Center
Career Start Year 2007
Number of shared co-authors 10
Icahn School of Medicine at Mount Sinai
Career Start Year 2005
Number of shared co-authors 8
Stanford University
Career Start Year 2004
Number of shared co-authors 23
University of Maryland School of Medicine
Career Start Year 2004
Number of shared co-authors 18
Schulich School of Medicine and Dentistry, Western University
Career Start Year 2003
Number of shared co-authors 1
Clinical Development
Career Start Year 2003
Number of shared co-authors 0
Harbin Medical University
Career Start Year 2002
Number of shared co-authors 4
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 8
Stanford University
Career Start Year 2000
Number of shared co-authors 18
Children's Hospital Oakland Research Institute
Career Start Year 1998
Number of shared co-authors 16
Center for Pharmacogenomics and Precision Medicine, University of Florida
Career Start Year 1998
Number of shared co-authors 21
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences
Career Start Year 1998
Number of shared co-authors 0
Durham VA Healthcare System and Duke University
Career Start Year 1998
Number of shared co-authors 9
The Ohio State University
Career Start Year 1997
Number of shared co-authors 4
and of Biochemistry and Pharmacy, University of Tuebingen
Career Start Year 1996
Number of shared co-authors 24
University of Pennsylvania Perelman School of Medicine
Career Start Year 1996
Number of shared co-authors 9
and University of Tuebingen, University of Tuebingen
Career Start Year 1995
Number of shared co-authors 5
Stanford University
Career Start Year 1995
Number of shared co-authors 22
University of Pennsylvania.
Career Start Year 1995
Number of shared co-authors 1
The University of Danang-University of Science and Technology
Career Start Year 1993
Number of shared co-authors 3
National Center for Toxicological Research
Career Start Year 1992
Number of shared co-authors 0
Marshall University, Joan C. Edwards School of Medicine
Career Start Year 1992
Number of shared co-authors 2
BC Children's Hospital Research Institute
Career Start Year 1991
Number of shared co-authors 4
St. George's University Medical School
Career Start Year 1990
Number of shared co-authors 3
University of South Dakota Sanford School of Medicine
Career Start Year 1989
Number of shared co-authors 27
UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill
Career Start Year 1984
Number of shared co-authors 7
Department of Pharmaceutics, University of Florida
Career Start Year 1979
Number of shared co-authors 16
Perelman School of Medicine, University of Pennsylvania
Career Start Year 1968
Number of shared co-authors 3

Collaborators

University of California San Francisco
Co-authored papers 19
University of Chicago
Co-authored papers 16
Center for Precision Medicine and Functional Genomics, Utah Tech University
Co-authored papers 12
Duke University
Co-authored papers 12
Genentech Inc.
Co-authored papers 11
Co-authored papers 9
University of California San Francisco
Co-authored papers 9
Department of Pharmaceutical Chemistry, University of California San Francisco
Co-authored papers 9
Center for Visualization, Washington State University
Co-authored papers 8
University of California San Francisco
Co-authored papers 8
University of California san francisco
Co-authored papers 8
Sapporo Medical University
Co-authored papers 7
Stanford University
Co-authored papers 6
Department of Pharmaceutical Chemistry, University of California San Francisco
Co-authored papers 6
Stanford University School of Medicine
Co-authored papers 6
University of Toledo
Co-authored papers 6
Co-authored papers 6
University of California San Francisco
Co-authored papers 5
University of California San Francisco
Co-authored papers 5
University of California san francisco
Co-authored papers 5
Japanese Foundation for Cancer Research
Co-authored papers 5
Departments of Pharmaceutical Sciences.
Co-authored papers 5
University of California san francisco
Co-authored papers 5
University of Chicago
Co-authored papers 5
University of California los angeles
Co-authored papers 4
University of California san francisco
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Vanderbilt University Medical Center
Co-authored papers 4
Albert Einstein College of Medicine
Co-authored papers 4